Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.50 |
| ▸ | PBK | Q96KB5 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.47 |
| ▸ | CDK2AP1 | O14519 | 7/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270577 | 1.00 | EED (0.50) | EEDPBKPARP1CHEK1CDK2AP1 | |
| SCHEMBL7259989 | 0.81 | EED (0.60) | EEDCHRNA1CHRNB2CHRNB4CHRNA4 | |
| Hydrochloric Acid SCHEMBL7243486 | 0.81 | EED (0.59) | EEDCHEK1CHRNA1CHRNB2CHRNB4 | |
| SCHEMBL5654175 | 0.75 | CHEK1 (0.60) | PBKPARP1CHEK1CDK2AP1CCNA2 | |
| SCHEMBL7673369 | 0.75 | CHEK1 (0.56) | PBKPARP1CHEK1CDK2AP1 | |
| SCHEMBL31227213 | 0.75 | CHEK1 (0.60) | PBKPARP1CHEK1CDK2AP1CCNA2 | |
| SCHEMBL1278937 | 0.75 | NPC1 (0.69) | PBKPARP1CHEK1CDK2AP1 | |
| SCHEMBL1278935 | 0.75 | NPC1 (0.69) | PBKPARP1CHEK1CDK2AP1 | |
| SCHEMBL1674869 | 0.75 | NPC1 (0.69) | PBKPARP1CHEK1CDK2AP1 | |
| SCHEMBL29392153 | 0.75 | CHEK1 (0.56) | PBKPARP1CHEK1CDK2AP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133901-B2 | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2094685-B1 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2094685-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008065626-A2 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVESAS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | HCRTR1, HCRTR2, NPY1R | EED 3228/4885PBK 4331/4885PARP1 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.